 Kenneth Boyer
Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Toxoplasmosis, Congenital | 19 | 2015 | 26 | 2.030 |
Why?
| | Toxoplasma | 12 | 2017 | 19 | 1.300 |
Why?
| | Antibiotic Prophylaxis | 3 | 2016 | 37 | 0.830 |
Why?
| | Toxoplasmosis | 5 | 2017 | 11 | 0.740 |
Why?
| | Cesarean Section | 1 | 2016 | 33 | 0.620 |
Why?
| | Pregnancy | 14 | 2016 | 457 | 0.590 |
Why?
| | Streptococcal Infections | 4 | 1998 | 17 | 0.570 |
Why?
| | Streptococcus agalactiae | 4 | 1998 | 8 | 0.510 |
Why?
| | Antibodies, Protozoan | 6 | 2017 | 12 | 0.480 |
Why?
| | Food Contamination | 1 | 2011 | 4 | 0.450 |
Why?
| | Toxoplasmosis, Ocular | 6 | 2008 | 7 | 0.430 |
Why?
| | Eating | 1 | 2011 | 61 | 0.430 |
Why?
| | Infant, Newborn | 19 | 2015 | 754 | 0.420 |
Why?
| | Pregnancy Complications, Parasitic | 6 | 2011 | 7 | 0.420 |
Why?
| | Pregnancy Complications, Infectious | 3 | 1998 | 34 | 0.360 |
Why?
| | Antiprotozoal Agents | 5 | 2008 | 13 | 0.350 |
Why?
| | Prenatal Diagnosis | 2 | 2005 | 21 | 0.290 |
Why?
| | Measles Vaccine | 1 | 2005 | 3 | 0.290 |
Why?
| | Measles | 1 | 2005 | 3 | 0.280 |
Why?
| | Infant | 15 | 2020 | 642 | 0.280 |
Why?
| | Immunoassay | 2 | 2017 | 45 | 0.270 |
Why?
| | Humans | 37 | 2020 | 31481 | 0.240 |
Why?
| | Sulfadiazine | 10 | 2008 | 11 | 0.230 |
Why?
| | Infectious Disease Transmission, Vertical | 3 | 2000 | 20 | 0.220 |
Why?
| | Immunoglobulin G | 3 | 2017 | 134 | 0.210 |
Why?
| | Female | 21 | 2016 | 18253 | 0.210 |
Why?
| | Pyrimethamine | 11 | 2008 | 13 | 0.210 |
Why?
| | Phenotype | 2 | 2020 | 379 | 0.210 |
Why?
| | Noonan Syndrome | 1 | 2020 | 2 | 0.200 |
Why?
| | Myeloproliferative Disorders | 1 | 2020 | 6 | 0.200 |
Why?
| | Immunoglobulin M | 2 | 2017 | 21 | 0.200 |
Why?
| | ras Proteins | 1 | 2020 | 14 | 0.200 |
Why?
| | Tachycardia, Ventricular | 1 | 2020 | 35 | 0.200 |
Why?
| | Anti-Bacterial Agents | 2 | 2016 | 412 | 0.190 |
Why?
| | Chorioretinitis | 2 | 2008 | 3 | 0.170 |
Why?
| | Hydrocephalus | 2 | 2015 | 31 | 0.150 |
Why?
| | Genotype | 2 | 2015 | 423 | 0.150 |
Why?
| | Family Health | 1 | 2015 | 38 | 0.150 |
Why?
| | Cluster Analysis | 1 | 2015 | 55 | 0.150 |
Why?
| | Fathers | 1 | 2015 | 27 | 0.140 |
Why?
| | Child, Preschool | 9 | 2015 | 786 | 0.140 |
Why?
| | Surgical Wound Infection | 1 | 2016 | 106 | 0.140 |
Why?
| | Child | 10 | 2015 | 1572 | 0.140 |
Why?
| | Polymerase Chain Reaction | 2 | 2005 | 188 | 0.120 |
Why?
| | Adult | 9 | 2011 | 9779 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 148 | 0.120 |
Why?
| | Antigens, Protozoan | 2 | 2011 | 4 | 0.110 |
Why?
| | Oocysts | 1 | 2011 | 3 | 0.110 |
Why?
| | North America | 1 | 2011 | 44 | 0.110 |
Why?
| | Drug Therapy, Combination | 5 | 2008 | 265 | 0.110 |
Why?
| | Protozoan Proteins | 1 | 2011 | 2 | 0.110 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 38 | 0.110 |
Why?
| | Cohort Studies | 4 | 2015 | 2014 | 0.110 |
Why?
| | Leucovorin | 7 | 2008 | 17 | 0.100 |
Why?
| | Adolescent | 6 | 2015 | 2667 | 0.090 |
Why?
| | Male | 12 | 2020 | 17583 | 0.090 |
Why?
| | Choroidal Neovascularization | 1 | 2008 | 2 | 0.090 |
Why?
| | Retinal Hemorrhage | 1 | 2008 | 3 | 0.090 |
Why?
| | Risk Factors | 4 | 2005 | 2664 | 0.090 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2008 | 17 | 0.090 |
Why?
| | Collagen Type II | 1 | 2008 | 36 | 0.090 |
Why?
| | Eosinophilia | 2 | 2006 | 49 | 0.090 |
Why?
| | Vision Disorders | 2 | 2006 | 26 | 0.090 |
Why?
| | Cataract | 1 | 2007 | 20 | 0.090 |
Why?
| | Animals | 9 | 2011 | 5312 | 0.080 |
Why?
| | Retinal Diseases | 1 | 2007 | 10 | 0.080 |
Why?
| | Epigenesis, Genetic | 1 | 2008 | 95 | 0.080 |
Why?
| | Incidence | 4 | 2015 | 829 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 301 | 0.080 |
Why?
| | Sepsis | 1 | 1988 | 157 | 0.080 |
Why?
| | Drug Hypersensitivity | 1 | 2006 | 18 | 0.080 |
Why?
| | Larva Migrans, Visceral | 1 | 1985 | 1 | 0.070 |
Why?
| | Nematode Infections | 1 | 1985 | 2 | 0.070 |
Why?
| | Raccoons | 1 | 1985 | 2 | 0.070 |
Why?
| | Meningoencephalitis | 1 | 1985 | 10 | 0.070 |
Why?
| | Morbillivirus | 1 | 2005 | 2 | 0.070 |
Why?
| | Practice Guidelines as Topic | 2 | 1998 | 389 | 0.070 |
Why?
| | Visual Acuity | 3 | 2008 | 48 | 0.060 |
Why?
| | Prevalence | 2 | 2015 | 544 | 0.060 |
Why?
| | United States | 3 | 2017 | 2539 | 0.050 |
Why?
| | Brain | 4 | 2011 | 1655 | 0.050 |
Why?
| | Heterozygote | 1 | 2020 | 115 | 0.050 |
Why?
| | Recurrence | 3 | 2007 | 389 | 0.050 |
Why?
| | Toxoplasmosis, Cerebral | 2 | 1996 | 3 | 0.050 |
Why?
| | Chicago | 3 | 2015 | 955 | 0.050 |
Why?
| | Calcinosis | 2 | 1996 | 53 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2006 | 1075 | 0.040 |
Why?
| | Wiskott-Aldrich Syndrome | 1 | 1997 | 1 | 0.040 |
Why?
| | Keratitis, Herpetic | 1 | 1997 | 1 | 0.040 |
Why?
| | Herpesvirus 1, Human | 1 | 1997 | 3 | 0.040 |
Why?
| | Acyclovir | 1 | 1997 | 6 | 0.040 |
Why?
| | Mutation | 1 | 2020 | 464 | 0.040 |
Why?
| | Prospective Studies | 3 | 2008 | 1934 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2017 | 16 | 0.040 |
Why?
| | Developing Countries | 1 | 2017 | 22 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2017 | 39 | 0.040 |
Why?
| | Lymphadenitis | 1 | 1996 | 2 | 0.040 |
Why?
| | Fertilization | 1 | 1996 | 5 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 1997 | 153 | 0.040 |
Why?
| | Antiviral Agents | 1 | 1997 | 139 | 0.040 |
Why?
| | Longitudinal Studies | 3 | 2008 | 1452 | 0.040 |
Why?
| | Agglutination Tests | 1 | 2015 | 5 | 0.040 |
Why?
| | Serogroup | 1 | 2015 | 3 | 0.040 |
Why?
| | Algorithms | 1 | 1998 | 412 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 580 | 0.040 |
Why?
| | Tetanus Toxoid | 1 | 1995 | 10 | 0.040 |
Why?
| | Fetal Diseases | 1 | 1995 | 10 | 0.040 |
Why?
| | Intelligence | 1 | 1995 | 28 | 0.030 |
Why?
| | Vaccination | 1 | 1995 | 43 | 0.030 |
Why?
| | Treatment Outcome | 4 | 2008 | 3910 | 0.030 |
Why?
| | Serotyping | 1 | 2012 | 12 | 0.030 |
Why?
| | Virulence | 1 | 2012 | 13 | 0.030 |
Why?
| | Hearing Loss, Sensorineural | 1 | 1992 | 17 | 0.030 |
Why?
| | Alleles | 1 | 2012 | 221 | 0.030 |
Why?
| | Meat | 1 | 2011 | 2 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 10 | 0.030 |
Why?
| | Swine Diseases | 1 | 2011 | 6 | 0.030 |
Why?
| | Cats | 1 | 2011 | 79 | 0.030 |
Why?
| | Swine | 1 | 2011 | 117 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2006 | 257 | 0.030 |
Why?
| | Blotting, Western | 1 | 2011 | 225 | 0.030 |
Why?
| | Infant, Newborn, Diseases | 2 | 1996 | 18 | 0.030 |
Why?
| | Lymphocytes | 1 | 1990 | 113 | 0.020 |
Why?
| | Feasibility Studies | 2 | 2006 | 281 | 0.020 |
Why?
| | Cell Line | 1 | 2011 | 360 | 0.020 |
Why?
| | Mice | 2 | 2011 | 1894 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2008 | 14 | 0.020 |
Why?
| | Vitreous Body | 1 | 2008 | 7 | 0.020 |
Why?
| | Genomic Imprinting | 1 | 2008 | 2 | 0.020 |
Why?
| | Eye | 1 | 2008 | 7 | 0.020 |
Why?
| | Injections | 1 | 2008 | 59 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2008 | 43 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2008 | 24 | 0.020 |
Why?
| | Cataract Extraction | 1 | 2007 | 4 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2008 | 136 | 0.020 |
Why?
| | Vision, Monocular | 1 | 2006 | 3 | 0.020 |
Why?
| | Vision, Binocular | 1 | 2006 | 3 | 0.020 |
Why?
| | Gram-Negative Bacteria | 1 | 1986 | 37 | 0.020 |
Why?
| | Wechsler Scales | 1 | 2006 | 15 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2006 | 17 | 0.020 |
Why?
| | Macula Lutea | 1 | 2006 | 9 | 0.020 |
Why?
| | Pattern Recognition, Visual | 1 | 2006 | 35 | 0.020 |
Why?
| | Language Tests | 1 | 2006 | 38 | 0.020 |
Why?
| | Ascaridoidea | 1 | 1985 | 1 | 0.020 |
Why?
| | Larva | 1 | 1985 | 3 | 0.020 |
Why?
| | Infant, Premature | 1 | 1986 | 226 | 0.020 |
Why?
| | Young Adult | 1 | 2011 | 2277 | 0.020 |
Why?
| | Obstetrics and Gynecology Department, Hospital | 1 | 1983 | 4 | 0.020 |
Why?
| | Hospital Departments | 1 | 1983 | 9 | 0.020 |
Why?
| | Milk, Human | 1 | 1986 | 186 | 0.020 |
Why?
| | Patient Isolation | 1 | 1983 | 24 | 0.020 |
Why?
| | Patient Care Planning | 1 | 1983 | 58 | 0.020 |
Why?
| | Pilot Projects | 2 | 1994 | 455 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2006 | 1240 | 0.010 |
Why?
| | Cross Infection | 1 | 1983 | 293 | 0.010 |
Why?
| | Eye Diseases | 1 | 2000 | 7 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 1996 | 891 | 0.010 |
Why?
| | Follow-Up Studies | 2 | 1996 | 2028 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2000 | 467 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 1997 | 96 | 0.010 |
Why?
| | Cognition | 1 | 2006 | 1206 | 0.010 |
Why?
| | Immunocompetence | 1 | 1996 | 7 | 0.010 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 1996 | 12 | 0.010 |
Why?
| | Lymph Nodes | 1 | 1996 | 84 | 0.010 |
Why?
| | Anti-Infective Agents | 1 | 1996 | 59 | 0.010 |
Why?
| | Psychological Tests | 1 | 1995 | 63 | 0.010 |
Why?
| | Motor Skills | 1 | 1995 | 64 | 0.010 |
Why?
| | Spiramycin | 1 | 1994 | 1 | 0.010 |
Why?
| | Chemistry, Pharmaceutical | 1 | 1994 | 11 | 0.010 |
Why?
| | Prenatal Care | 1 | 1994 | 9 | 0.010 |
Why?
| | Seizures | 1 | 1995 | 88 | 0.010 |
Why?
| | Neutropenia | 1 | 1994 | 26 | 0.010 |
Why?
| | Mothers | 1 | 1996 | 192 | 0.010 |
Why?
| | Child Development | 1 | 1995 | 78 | 0.010 |
Why?
| | Brain Diseases | 1 | 1994 | 90 | 0.010 |
Why?
| | Physical Examination | 1 | 1994 | 116 | 0.010 |
Why?
| | Nervous System Diseases | 1 | 1995 | 145 | 0.010 |
Why?
| | Phenobarbital | 1 | 1992 | 5 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1992 | 43 | 0.010 |
Why?
| | Audiometry, Evoked Response | 1 | 1992 | 1 | 0.010 |
Why?
| | Concanavalin A | 1 | 1990 | 3 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1990 | 9 | 0.010 |
Why?
| | Time Factors | 1 | 1996 | 1902 | 0.010 |
Why?
| | Interleukin-2 | 1 | 1990 | 69 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1990 | 120 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1990 | 221 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 1994 | 1273 | 0.010 |
Why?
| | Retrospective Studies | 1 | 1996 | 3591 | 0.010 |
Why?
| | Peritoneum | 1 | 1986 | 19 | 0.000 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1986 | 16 | 0.000 |
Why?
| | Enteral Nutrition | 1 | 1986 | 64 | 0.000 |
Why?
| | Risk | 1 | 1986 | 228 | 0.000 |
Why?
| | Hospital Bed Capacity, 500 and over | 1 | 1983 | 9 | 0.000 |
Why?
| | Nurseries, Hospital | 1 | 1983 | 5 | 0.000 |
Why?
| | Maternal-Fetal Exchange | 1 | 1983 | 11 | 0.000 |
Why?
| | Policy Making | 1 | 1983 | 16 | 0.000 |
Why?
| | Breast Feeding | 1 | 1983 | 177 | 0.000 |
Why?
|
|
Boyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|